Amarin Corp Plc (AMRN)

[Biobillionair]

Speculation of the biggest secondary indication (on-label) derived out of R-I data:
1) NASH / Fatty liver disease

NASH leads to liver failure, kidney failure, pulmonary hypertension and then death; it's a huge healthcare expenditure. Vascepa used in this patient population could additionally save billions in healthcare dollars.

Amarin as a number of approved and pending patent applications for the treatment of NASH.

BB